Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. - Dreyzin A; Kramer AM; Yates B; Wang HW; Sahaf B; Yuan C; Klysz D; Tunuguntla R; Ehlinger Z; Reitberg S; Adebola S; Su A; et al. (Cytotherapy, 2026)